Search: onr:"swepub:oai:lup.lub.lu.se:8f89836f-951f-4493-948a-d66dfb6cbbf2" > Reproductive risk f...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04788naa a2200481 4500 | |
001 | oai:lup.lub.lu.se:8f89836f-951f-4493-948a-d66dfb6cbbf2 | |
003 | SwePub | |
008 | 160401s2007 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/11385642 URI |
024 | 7 | a https://doi.org/10.1016/S1470-2045(06)70983-42 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a McLaughlin, John R4 aut |
245 | 1 0 | a Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study |
264 | 1 | c 2007 |
520 | a BACKGROUND: Several of the known risk factors for ovarian cancer are thought to act through their effects on ovulation and the menstrual cycle, such as parity, breastfeeding, and use of oral contraceptives. We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes. METHODS: We did a matched case-control study in women who were found to carry a pathogenetic mutation in BRCA1 or BRCA2. Participants were derived from a population-based study of ovarian cancer in Ontario, Canada, and from an international registry of mutation carriers based in Toronto, ON, Canada. All participants completed a written questionnaire that detailed their reproductive history. Women with invasive ovarian cancer and controls were matched on year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of breast cancer. The odds ratios and 95% CI for ovarian cancer were estimated with respect to use of oral contraceptives, parity, breastfeeding, and tubal ligation. FINDINGS: Questionnaires were completed by 799 women with a history of invasive ovarian cancer (670 with BRCA1 mutations, 128 with BRCA2 mutations, and one with a mutation in both genes), and controls were 2424 women without ovarian cancer (2043 with BRCA1 mutations, 380 with BRCA2 mutations, and one with a mutation in both genes). Use of oral contraceptives reduced the risk of ovarian cancer in carriers of BRCA1 mutations (odds ratio 0.56 [95% CI 0.45-0.71]; p<0.0001) and carriers of BRCA2 mutations (0.39 [0.23-0.66]; p=0.0004). Parity was associated with a reduced risk for carriers of BRCA1 mutations (0.67 [0.46-0.96]; p=0.03), but with an increased risk for those with BRCA2 mutations (2.74 [1.18-6.41]; p=0.02). Breastfeeding was associated with a reduced risk for carriers of BRCA1 mutations (0.74 [0.56-0.97]; p=0.03). An effect of similar magnitude was seen for carriers of BRCA2 mutations (0.72 [0.41-1.29]; p=0.27), but this was not statistically significant. The association with tubal ligation was not significant for carriers of BRCA1 mutations (0.80 [0.59-1.08]; p=0.15), or for carriers of BRCA2 mutations (0.63 [0.34-1.15]; p=0.13). INTERPRETATION: Oral contraceptives could be used as a means to prevent ovarian cancer in carriers of BRCA1 and BRCA2 mutations. The possible adverse effect of parity on ovarian-cancer risk in women with a BRCA2 mutation needs further study. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Risch, Harvey A4 aut |
700 | 1 | a Lubinski, Jan4 aut |
700 | 1 | a Moller, Pal4 aut |
700 | 1 | a Ghadirian, Parviz4 aut |
700 | 1 | a Lynch, Henry4 aut |
700 | 1 | a Karlan, Beth4 aut |
700 | 1 | a Fishman, David4 aut |
700 | 1 | a Rosen, Barry4 aut |
700 | 1 | a Neuhausen, Susan L4 aut |
700 | 1 | a Offit, Kenneth4 aut |
700 | 1 | a Kauff, Noah4 aut |
700 | 1 | a Domchek, Susan4 aut |
700 | 1 | a Tung, Nadine4 aut |
700 | 1 | a Friedman, Eitan4 aut |
700 | 1 | a Foulkes, William4 aut |
700 | 1 | a Olsson, Håkanu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Institutionen för kliniska vetenskaper, Lund,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Department of Clinical Sciences, Lund,Breastcancer-genetics,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-hol |
700 | 1 | a Hereditary Ovarian Cancer Clinical Study Group, and4 aut |
710 | 2 | a Medicinsk onkologib Sektion I4 org |
773 | 0 | t The Lancet Oncologyg 8:1, s. 26-34q 8:1<26-34x 1474-5488 |
856 | 4 | u http://dx.doi.org/10.1016/S1470-2045(06)70983-4y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/1138564 |
856 | 4 8 | u https://doi.org/10.1016/S1470-2045(06)70983-4 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view